Daily10d
Transanal TME Proves Noninferior to Laparoscopic Approach in 3-Year Disease-Free Survival for Rectal Cancer: TaLaR Trial
The 3-year local recurrence rate was 3.6% for transanal TME and 4.4% for laparoscopic TME. The 3-year overall survival was 92 ...
Seeking Alpha13d
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
That is, it will have to achieve success with respect to the efficacy endpoint of disease-free survival [DFS]. There are three aspects relating to this specific DFS endpoint to be evaluated ...
Business Wire3d
Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.